Lanepitant HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598286

CAS#: 170508-05-1

Description: Lanepitant HCl is a potent non-peptide neurokinin-1 receptor antagonist, inhibits neurogenic dural inflammation.

Chemical Structure

Lanepitant HCl
CAS# 170508-05-1

Theoretical Analysis

MedKoo Cat#: 598286
Name: Lanepitant HCl
CAS#: 170508-05-1
Chemical Formula: C33H47Cl2N5O3
Exact Mass:
Molecular Weight: 632.67
Elemental Analysis: C, 62.65; H, 7.49; Cl, 11.21; N, 11.07; O, 7.59

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 167678-33-3 (HCl Trihydrate)  

Synonym: Lanepitant dihydrochloride; LY-303870 dihydrochloride; LY 303870 dihydrochloride; LY303870 dihydrochloride;

IUPAC/Chemical Name: (R)-N-(1-(1H-indol-3-yl)-3-(N-(2-methoxybenzyl)acetamido)propan-2-yl)-2-([1,4'-bipiperidin]-1'-yl)acetamide dihydrochloride


InChi Code: InChI=1S/C33H45N5O3.2ClH/c1-25(39)38(22-26-10-4-7-13-32(26)41-2)23-28(20-27-21-34-31-12-6-5-11-30(27)31)35-33(40)24-36-18-14-29(15-19-36)37-16-8-3-9-17-37;;/h4-7,10-13,21,28-29,34H,3,8-9,14-20,22-24H2,1-2H3,(H,35,40);2*1H/t28-;;/m1../s1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 632.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Bignami F, Giacomini C, Lorusso A, Aramini A, Rama P, Ferrari G. NK1 receptor antagonists as a new treatment for corneal neovascularization. Invest Ophthalmol Vis Sci. 2014 Sep 16;55(10):6783-94. doi: 10.1167/iovs.14-14553. PubMed PMID: 25228541.

2: Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia. 1997 Nov;17(7):785-90. PubMed PMID: 9399010.

3: Goldstein DJ, Wang O, Todd LE, Gitter BD, DeBrota DJ, Iyengar S. Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Clin Pharmacol Ther. 2000 Apr;67(4):419-26. PubMed PMID: 10801252.

4: Goldstein DJ, Offen WW, Klein EG, Phebus LA, Hipskind P, Johnson KW, Ryan RE Jr. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia. 2001 Mar;21(2):102-6. PubMed PMID: 11422091.

5: Goldstein DJ, Wang O, Gitter BD, Iyengar S. Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin Neuropharmacol. 2001 Jan-Feb;24(1):16-22. PubMed PMID: 11290877.

6: Chaïr-Yousfi I, Laraba-Djebari F, Hammoudi-Triki D. Androctonus australis hector venom contributes to the interaction between neuropeptides and mast cells in pulmonary hyperresponsiveness. Int Immunopharmacol. 2015 Mar;25(1):19-29. doi: 10.1016/j.intimp.2015.01.008. Epub 2015 Jan 16. PubMed PMID: 25601496.

7: Wei T, Guo TZ, Li WW, Kingery WS, Clark JD. Acute versus chronic phase mechanisms in a rat model of CRPS. J Neuroinflammation. 2016 Jan 19;13:14. doi: 10.1186/s12974-015-0472-8. PubMed PMID: 26785976; PubMed Central PMCID: PMC4719337.

8: Yang X, Zhao H, Shi H, Wang X, Zhang S, Zhang Z, Zu J, Zhang W, Shen X, Cui G, Hua F. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. Exp Neurol. 2015 Sep;271:168-74. doi: 10.1016/j.expneurol.2015.05.007. Epub 2015 May 20. PubMed PMID: 26001615.

9: Shi X, Wang L, Clark JD, Kingery WS. Keratinocytes express cytokines and nerve growth factor in response to neuropeptide activation of the ERK1/2 and JNK MAPK transcription pathways. Regul Pept. 2013 Sep 10;186:92-103. doi: 10.1016/j.regpep.2013.08.001. Epub 2013 Aug 17. PubMed PMID: 23958840; PubMed Central PMCID: PMC3799830.

10: Li WW, Guo TZ, Liang DY, Sun Y, Kingery WS, Clark JD. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology. 2012 Apr;116(4):882-95. doi: 10.1097/ALN.0b013e31824bb303. PubMed PMID: 22343473; PubMed Central PMCID: PMC3311711.

11: Sahbaie P, Shi X, Li X, Liang D, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, David Clark J. Preprotachykinin-A gene disruption attenuates nociceptive sensitivity after opioid administration and incision by peripheral and spinal mechanisms in mice. J Pain. 2012 Oct;13(10):997-1007. doi: 10.1016/j.jpain.2012.07.009. PubMed PMID: 23031399; PubMed Central PMCID: PMC3491068.

12: Phebus LA, Johnson KW, Stengel PW, Lobb KL, Nixon JA, Hipskind PA. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci. 1997;60(18):1553-61. PubMed PMID: 9126877.

13: Gehlert DR, Schober DA, Hipskind PA, Gitter BD, Howbert JJ. [3H]LY303870, a novel nonpeptide radioligand for the NK-1 receptor. J Neurochem. 1996 Mar;66(3):1095-102. PubMed PMID: 8769871.

14: Sahbaie P, Shi X, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, Clark JD. Role of substance P signaling in enhanced nociceptive sensitization and local cytokine production after incision. Pain. 2009 Oct;145(3):341-9. doi: 10.1016/j.pain.2009.06.037. Epub 2009 Aug 5. PubMed PMID: 19660865; PubMed Central PMCID: PMC2746201.

15: Sendo T, Itoh Y, Goromaru T, Hirakawa T, Ishida M, Nakano H, Oishi R. Role of substance P in hypersensitivity reactions induced by paclitaxel, an anticancer agent. Peptides. 2004 Jul;25(7):1205-8. PubMed PMID: 15245881.

16: Campbell EA, Gentry CT, Patel S, Panesar MS, Walpole CS, Urban L. Selective neurokinin-1 receptor antagonists are anti-hyperalgesic in a model of neuropathic pain in the guinea-pig. Neuroscience. 1998 Dec;87(3):527-32. PubMed PMID: 9758219.

17: Li WW, Guo TZ, Liang D, Shi X, Wei T, Kingery WS, Clark JD. The NALP1 inflammasome controls cytokine production and nociception in a rat fracture model of complex regional pain syndrome. Pain. 2009 Dec 15;147(1-3):277-86. doi: 10.1016/j.pain.2009.09.032. Epub 2009 Oct 22. PubMed PMID: 19853379; PubMed Central PMCID: PMC5515229.

18: Sonea IM, Palmer MV, Akili D, Harp JA. Treatment with neurokinin-1 receptor antagonist reduces severity of inflammatory bowel disease induced by Cryptosporidium parvum. Clin Diagn Lab Immunol. 2002 Mar;9(2):333-40. PubMed PMID: 11874873; PubMed Central PMCID: PMC119952.

19: Kingery WS, Davies MF, Clark JD. A substance P receptor (NK1) antagonist can reverse vascular and nociceptive abnormalities in a rat model of complex regional pain syndrome type II. Pain. 2003 Jul;104(1-2):75-84. PubMed PMID: 12855316.

20: Deschamps K, Couture R. The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation. Br J Pharmacol. 2005 Jul;145(6):712-27. PubMed PMID: 15895109; PubMed Central PMCID: PMC1576198.